UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 100.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 16,511 shares of the company’s stock after purchasing an additional 8,262 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Dr. Reddy’s Laboratories were worth $261,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in RDY. EverSource Wealth Advisors LLC lifted its stake in Dr. Reddy’s Laboratories by 423.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company’s stock worth $29,000 after purchasing an additional 1,507 shares in the last quarter. Glass Jacobson Investment Advisors llc lifted its stake in Dr. Reddy’s Laboratories by 400.0% during the 4th quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company’s stock worth $32,000 after acquiring an additional 1,600 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in Dr. Reddy’s Laboratories by 461.0% during the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company’s stock valued at $40,000 after acquiring an additional 2,093 shares during the period. Allworth Financial LP grew its position in Dr. Reddy’s Laboratories by 447.8% in the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock valued at $41,000 after acquiring an additional 2,230 shares in the last quarter. Finally, Sierra Ocean LLC acquired a new position in Dr. Reddy’s Laboratories in the 4th quarter valued at about $43,000. Hedge funds and other institutional investors own 3.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on RDY. Hsbc Global Res raised shares of Dr. Reddy’s Laboratories from a “hold” rating to a “strong-buy” rating in a research report on Thursday, June 5th. Wall Street Zen upgraded shares of Dr. Reddy’s Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. Finally, HSBC upgraded shares of Dr. Reddy’s Laboratories from a “hold” rating to a “buy” rating and boosted their price target for the stock from $14.44 to $16.90 in a research note on Thursday, June 5th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $16.95.

Dr. Reddy’s Laboratories Stock Performance

Shares of RDY opened at $16.14 on Friday. Dr. Reddy’s Laboratories Limited has a 1 year low of $12.26 and a 1 year high of $16.89. The stock has a market capitalization of $13.47 billion, a PE ratio of 25.70 and a beta of 0.33. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The stock has a 50-day simple moving average of $14.11 and a 200-day simple moving average of $14.08.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its earnings results on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.02. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The firm had revenue of $996.17 million for the quarter, compared to analysts’ expectations of $83.70 billion. On average, analysts predict that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.